A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...

Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial guidance, the company said. ・Genmab assumed sole responsibility for the ...

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

Starton Holdings plans $40M IPO for cancer drug delivery innovations, but weak IP and limited backing make this a potentially risky investment. Learn more about STA stock here.

Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key secondary endpoints in the pivotal RINGSIDE trial. Immunome is planning an FDA ...

Trial sponsors are typically responsible for providing the experimental drug or treatment at no cost to patients. However, ...

Diabetes drugs may be doing more than managing blood sugar, they could also shape cancer biology in unexpected ways.

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...